Introduction:
GlaxoSmithKline Pharmaceuticals (GSK Pharma) will invest Rs 1000 crore for greenfield manufacturing facility at Vemgal near Bengaluru, India.
Features:
The greenfield facility, which will have an installed capacity of over 9 billion tablets and capsules per year, is expected to be operational by 2017.
The new site, which represents up to Rs 1,000 crore in investments, will be the first greenfield pharma site GSK has built across the globe over the past 10 years.The new unit is part of the strategic plan to rationalize, streamline and reduce costs in the supply network, whilst increasing capacity to meet the growing demands for important medicines, the company said.
GSK India is also upgrading the Nashik site by investing in infrastructure across all areas with special focus on good manufacturing practices (GMP), safety and sustainability.
The company's Nashik facility, continuing its journey on roadmap of long-term strategy, has made significant progress in terms of building capability. It has completed enhancement of the existing Eltroxin facility in safety standards. The unit is ready to launch new products in Bactroban creams early next year.
Specifications:
| Company Name | GlaxoSmithKline Pharmaceuticals |
| Location | Bengaluru, India |
| Type | Manufacturing Facility |
| Estimated Cost | Rs 1000 crore |
| Operations Starts | 2017 |
